Equity Research · Current Holding
UnitedHealth Group
UNH · NYSE · Managed Care · Health Services
Rating
Overweight
Price Target
$500
Quan Pham, Senior Analyst · M’Squared Capital Research · As of Q2 2026
A best-in-class compounder handed to us at a crisis multiple after a once-in-a-decade sentiment washout.
Summary
A cluster of shocks — a medical-loss-ratio spike, a DOJ headline cycle, a leadership transition, and withdrawn guidance — repriced UnitedHealth from premium to distressed. The integrated Optum-plus-insurance model is intact and cost trend is normalizing. We bought a trough multiple on a durable, recurring earnings stream.
Business Overview
UnitedHealth is the largest US managed-care organization (UnitedHealthcare) fused with Optum — health services, OptumRx pharmacy, and Optum Health care delivery. The vertical integration is the widest moat in healthcare services.
Investment Thesis
- 01
Sentiment washout is not franchise impairment
The earnings power of Optum and the risk-based model is intact. The drawdown was multiple compression on a headline cycle, not a structural break in the business.
- 02
Cost trend normalizes
Elevated utilization is cyclical, not permanent. Pricing catches up on the 1/1 renewal cycle, restoring the underwriting margin over the course of 2026.
- 03
A trough valuation on a compounder
Roughly 13x normalized EPS on a mid-teens grower with 90%-plus recurring revenue is a valuation we are very rarely offered in this name.
Valuation & Price Target
Our $500 target is ~18x normalized 2027E EPS — still below the historical average multiple, on earnings we regard as trough. The asymmetry comes from buying quality when the multiple, not the franchise, is broken.
Catalysts
- Medical-loss-ratio stabilization in quarterly prints
- 2026 rate and benefit-design repricing
- Resolution of the DOJ and regulatory overhang
- New-CEO strategic reset and guidance reinstatement
Key Risks
- Further regulatory or DOJ escalation
- Medicare Advantage rate pressure and the V28 risk-model phase-in
- Cost trend proving structural rather than cyclical
Bottom Line
Buying quality in crisis is the highest-expectancy trade in our playbook. Overweight, $500 target.
This note is the opinion of M’Squared Capital and is provided for informational purposes only. It is not investment advice, nor an offer or solicitation to buy or sell any security. Price targets and entry and exit levels reflect the firm’s proprietary views and realized transactions; they are not forecasts of future results. The firm may hold, add to, reduce, or close any position at any time without notice. Past performance is not indicative of future results.